Pavel Printsev

Director

Pavel Printsev is the Director of Business Development at Bridge Biotherapeutics, a publicly-traded, South Korean, clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs, including ulcerative colitis, fibrotic diseases, and cancers. The company also has an independently run research center in Boston, USA, that is developing its own in-house discovery programs, currently focusing on oncology.

Pavel has been living and working in South Korea for over ten years, where he has helped several domestic pharma, venture capital, and biotech companies expand and grow their businesses abroad. Pavel is also involved in company creation, as he serves as a panelist on Baselaunch’s (Basel-based biotech incubator and accelerator) selection and review committee.

Pavel graduated from the University of Toronto with a specialist degree in Chemistry and went on to receive his Master’s degree at Seoul National University in Organic Chemistry.